Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;101(4):602-9.
doi: 10.2105/AJPH.2010.300027. Epub 2011 Jan 13.

Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices

Sheila M Rothman  1 , Victoria H Raveis, Anne Friedman, David J Rothman
Affiliations

Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices

Sheila M Rothman et al. Am J Public Health. 2011 Apr.

Abstract

Health advocacy organizations (HAOs) are influential stakeholders in health policy. Although their advocacy tends to closely correspond with the pharmaceutical industry's marketing aims, the financial relationships between HAOs and the pharmaceutical industry have rarely been analyzed. We used Eli Lilly and Company's grant registry to examine its grant-giving policies. We also examined HAO Web sites to determine their grant-disclosure patterns. Only 25% of HAOs that received Lilly grants acknowledged Lilly's contributions on their Web sites, and only 10% acknowledged Lilly as a grant event sponsor. No HAO disclosed the exact amount of a Lilly grant. As highly trusted organizations, HAOs should disclose all corporate grants, including the purpose and the amount. Absent this disclosure, legislators, regulators, and the public cannot evaluate possible conflicts of interest or biases in HAO advocacy.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Lilly and Company's US sales and grants to US health advocacy organizations (HAOs), by therapeutic area, 2007.
See this image and copyright information in PMC

Comment in

References

    1. Markman M. The increasingly complex world of cancer patient advocacy organizations. Curr Oncol Rep. 2008;10(1):1–2 - PubMed
    1. American Diabetes Association Web site. Available at: http://www.diabetes.org. Accessed April 27, 2010.
    1. Batt S. Marching to different drummers: health advocacy groups in Canada and funding from the pharmaceutical industry. Available at: http://www.whp-apsf.ca/pdf/corpFunding.pdf. Published January 2005. Accessed January 4, 2011
    1. O'Donovan O. Corporate colonization of health activism? Irish health advocacy organizations' modes of engagement with pharmaceutical corporations. Int J Health Serv. 2007;37(4):711–733 - PubMed
    1. Mintzes B. Should patient groups accept money from drug companies? No. BMJ. 2007;334(7600):935. - PMC - PubMed

Publication types

LinkOut - more resources